EPLAW PATENT BLOG

UPC – Amgen v. Sanofi-Aventis

Posted: September 29th, 2023

Amgen, Inc. v. Sanofi-Aventis Deutschland GmbH, UPC, Court of First Instance – Munich (DE) Central Division, Judge-rapporteur Kupecz, 20 September 2023, Case no. UPC_CFI_1/2023

Rule 262.1(b) RoP requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence upon a request by a member of the public. To be informed of the proceedings before the Unified Patent Court for the purposes of education and training is not a legitimate reason as required by Rule 262.1(b) RoP. It is also insufficiently concrete and verifiable. No legal basis to give access to letter for service.

The entire decision can be read here.

Leave a Reply